The company reported its strongest Q1 in history, achieving record revenue, EBITDA, and PAT. Reported revenue stood at ₹22,424 lakhs (₹224.24 Cr), representing a 20.38% year-over-year (YoY) increase from ₹18,628 lakhs in Q1 FY26 and a 9.30% quarter-over-quarter (QoQ) increase from ₹20,516 lakhs in Q4 FY26.

EBITDA surged 53.03% YoY to ₹7,696 lakhs (₹76.96 Cr) from ₹5,029 lakhs, with margin expansion of 732 basis points to 34.32% from 27.00%. QoQ, EBITDA increased 14.00% from ₹6,751 lakhs, with margin improving 142 basis points from 32.90%.

Profit After Tax (PAT) grew 42.99% YoY to ₹5,039 lakhs (₹50.39 Cr) from ₹3,524 lakhs, and increased 7.12% QoQ from ₹4,704 lakhs. PAT margin expanded 355 basis points YoY to 22.47% from 18.92%, while declining 46 basis points QoQ from 22.93%.

Basic EPS reached ₹29.70, up 42.93% YoY from ₹20.78 and up 7.14% QoQ from ₹27.72. Diluted EPS was ₹29.69, up 43.02% YoY from ₹20.76 and up 7.15% QoQ from ₹27.71.

Headcount stood at 3,352, a 2.73% YoY increase from 3,263 and a 3.11% QoQ increase from 3,251. The company reported strong operating leverage, with revenue growing 20.38% YoY while headcount increased only 2.73%.

As of 30 June 2026, cash and cash equivalents stood at ₹13,802 lakhs (₹138.02 Cr), with outstanding borrowings of ₹3,762.50 lakhs (₹37.625 Cr).

Segment Performance

Research Solutions:

  • Reported revenue (including AJE) of ₹12,323 lakhs, up 13.22% YoY from ₹10,884 lakhs and up 3.08% QoQ from ₹11,955 lakhs
  • Excluding AJE, revenue was ₹9,746 lakhs, up 26.33% YoY from ₹7,715 lakhs and up 6.35% QoQ from ₹9,164 lakhs
  • EBITDA (including AJE) was ₹5,554 lakhs, up 37.88% YoY from ₹4,028 lakhs and up 11.71% QoQ from ₹4,972 lakhs
  • EBITDA margin (including AJE) expanded 806 basis points YoY to 45.07% from 37.01% and 348 basis points QoQ from 41.59%
  • Headcount was 2,452, up 8.40% YoY from 2,262 and up 4.47% QoQ from 2,347

Education Solutions:

  • Revenue grew 42.21% YoY to ₹7,341 lakhs from ₹5,162 lakhs and 22.09% QoQ from ₹6,013 lakhs
  • EBITDA increased 39.14% YoY to ₹2,574 lakhs from ₹1,850 lakhs and 11.38% QoQ from ₹2,311 lakhs
  • EBITDA margin was 35.06%, slightly down 78 basis points YoY from 35.84% and down 337 basis points QoQ from 38.43%
  • Headcount reduced 4.26% YoY to 765 from 799 and increased 0.39% QoQ from 762
  • Unbound Medicine contributed its first full quarter, adding recurring, high-renewal healthcare revenue

Corporate Learning:

  • Revenue grew 6.89% YoY to ₹2,760 lakhs from ₹2,582 lakhs and 8.32% QoQ from ₹2,548 lakhs
  • EBITDA surged 60.69% YoY to ₹699 lakhs from ₹435 lakhs and 4.33% QoQ from ₹670 lakhs
  • EBITDA margin expanded 848 basis points YoY to 25.33% from 16.85%, while declining 97 basis points QoQ from 26.30%
  • Headcount reduced 33.17% YoY to 135 from 202 and 4.93% QoQ from 142
  • Second consecutive quarter of growth with restructuring benefits flowing through

Core Performance Metrics (Excluding AJE)

  • Core revenue (excluding AJE) was ₹19,847 lakhs, up 28.38% YoY from ₹15,459 lakhs and 11.98% QoQ from ₹17,724 lakhs
  • Core EBITDA was ₹6,695 lakhs, up 56.53% YoY from ₹4,277 lakhs and 20.70% QoQ from ₹5,547 lakhs
  • Core EBITDA margin expanded 606 basis points YoY to 33.73% from 27.67% and 243 basis points QoQ from 31.30%
  • Core headcount was 3,253, up 3.70% YoY from 3,137 and 3.40% QoQ from 3,146

Business Diversification

  • Client diversification improved significantly with 841 clients billed in Q1 FY27 compared to 404 a year ago, driven by Unbound Medicine's institutional subscriber base
  • Revenue by geography: North America 49% (vs 51% in Q1 FY26), Europe 33% (vs 29%), Rest of the World 18% (vs 20%)
  • DSO (Days Sales Outstanding) improved to 45 days from 51 days in Q4 FY26, reflecting enhanced collection efficiency
  • Client concentration: Top 5 contributed 46% (vs 45% in Q1 FY26), Top 10 contributed 60% (vs 59%), Top 15 contributed 66% (vs 66%)

Guidance and Outlook

  • Company reiterated FY27 EBITDA guidance of over ₹300 Crores
  • Q1 EBITDA of ₹77 Cr represents approximately 26% of the full-year guidance, ahead of straight-line pace
  • Company noted that second half has historically outperformed first half
  • Guidance represents a ~21% three-year EBITDA CAGR from FY24 to FY27, built bottom-up from each segment operating plan
  • Company expects to "comfortably clear" the ₹300 Cr EBITDA mark rather than stretch toward it

Additional Information

  • The earnings presentation is available on the company's website at www.mpslimited.com under the Investors section
  • The document contains forward-looking statements subject to assumptions, risks, and uncertainties including the ability to successfully conclude and integrate potential acquisitions, and general regulatory and economic conditions
  • Figures for previous periods have been regrouped wherever necessary